IJR News

News

Standard Life's operating profit surges 25% despite £179m statutory loss — Sep 7, 2026Standard Life reported stronger-than-expected half-year results, with IFRS adjusted operating profit up 25% to £563m, while posting a £179m loss driven largely by planned investment spend; the group says it remains on track to deliver its 2026 targets and cites momentum across pensions, savings and capital-light businesses. The company also flagged the £2bn acquisition of Aegon UK and a UK pension risk transfer partnership as key catalysts for growth and enhanced cash generation, underpinning its upbeat outlook despite the H1 loss.

0

Dana Whitfield The Aegon deal is the real story here - if that integration goes smoothly it could actually justify some of this optimism.

Kari Lake Seeks Further Review by AZ Supreme Court of Alleged 35K Ballot DiscrepancyReporting — Apr 7, 2023Arizona Republican gubernatorial candidate Kari Lake doubled down in a brief filed Wednesday at the state Supreme Court on her claim that there are 35,563 unaccounted-for ballots that showed up in Maricopa County’s…

0

Bitdeer buys 200 Texas acres, aiming to scale Milam County power capacity — Sep 2, 2026Bitdeer completed a $100 million fee-simple acquisition of roughly 200 acres in Milam County, Texas adjacent to its Rockdale facility to support AI/HPC data-center expansion, granting outright ownership and expanding capacity toward 742 MW (563 MW online; 179 MW pipeline) while leaving interconnection and water-right details to be confirmed. The deal strengthens Bitdeer’s control over development, positions the Rockdale site for future power allocations and potential tenants, and situates the asset about 70 miles from Austin.

+1

Sam Okafor MW is a serious number - curious how ERCOT handles that interconnection request given all the other data centers piling into Texas grid right now.

Biotech firms award new hires stock options, some worth hundreds of thousands — Aug 31, 2026Several biopharma and biotech companies—X4 Pharmaceuticals, Aura Biosciences, Akebia Therapeutics, Abeona Therapeutics, and Faeth Therapeutics—awarded inducement equity grants to newly hired executives or employees under Nasdaq Listing Rule 5635(c)(4), including stock options (with Aura also granting RSUs) and with 10-year terms and multi-year vesting schedules designed to align new hires with company goals. Vesting generally starts with 25% after one year and proceeds in monthly or quarterly installments over the following three years, subject to continued employment, with exercise prices set to the grant-date closing price.

0

IJREgg Price Fixing Shouldn’t Be Just Another Cost Of Doing BusinessAngela Huffman · 4 min · 2h